首页> 外文会议>World congress on medical physics and biomedical engineering;International congress of the IUPESM >Delay and dispersion correction for simultaneous quantification of perfusion and permeability in the prostate using DCE-MRI with a dual-contrast sequence
【24h】

Delay and dispersion correction for simultaneous quantification of perfusion and permeability in the prostate using DCE-MRI with a dual-contrast sequence

机译:使用双对比序列的DCE-MRI进行延迟和弥散校正以同时量化前列腺的灌注和通透性

获取原文

摘要

The aim of the present study was to quantify both perfusion and extravasation in the prostate to discriminate tumor from healthy tissue, which might be achieved by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a nonspecific low-molecular-weight contrast medium (CM).To determine extravasation as well as tissue perfusion an inversion-prepared dual-contrast sequence employing a parallel acquisition technique (PAT) was designed for interleaved acquisition of Tl-weighted images for extravasation measurement and T2*-weighted images for determination of the highly concentrated bolus with a sufficiently high temporal and spatial resolution at an acceptable signal-to-noise ratio. Thirteen patients with proven prostate cancer were examined with the sequence using a combined body-array prostate coil. Before pharmacokinetic evaluation the images were intensity-corrected and, if required, motion-corrected. The pharmacokinetic model used to calculate perfusion, permeability, blood volume, interstitial volume, transit time, and vessel size index included two compartments and a correction of delay and dispersion of the arterial input function.The information provided by the dual-contrast sequence allowed application of a more elaborate model for evaluation and enabled quantification of all parameters. Peripheral prostate tumors were found to differ from peripheral healthy prostate tissue in perfusion (1.38 ml/(min>cm3) vs. 0.23 ml/(min>cm3), P=0.001), blood volume approximately two times higher, 1.9 % vs. 0.7 %; and mean transit time in tumors approximately half that of normal prostate tissue, 2.88±2.30 s vs. 4.88±3.21 s.A inversion-prepared dual-contrast sequence acquiring Tl-and T2*-weighted images with sufficient temporal resolution and signal-to-noise ratio was successfully applied in patients with prostate cancer to quantify all pharmacokinetic parameters of inflow and extravasation of a low-molecular-weight inert tracer.
机译:本研究的目的是量化前列腺的灌注和外渗,以区分肿瘤与健康组织,这可以通过使用非特异性低分子量造影剂进行动态造影增强磁共振成像(DCE-MRI)来实现(厘米)。 为了确定外渗以及组织灌注,设计了使用并行采集技术(PAT)的反演准备的双重对比序列,用于交错采集T1加权图像以进行外渗测量和T2 *加权图像以确定高浓度大剂量在可接受的信噪比下具有足够高的时间和空间分辨率。使用组合的人体阵列前列腺线圈,用该序列检查了13名已证明患有前列腺癌的患者。在药代动力学评估之前,对图像进行强度校正,如果需要,还可以进行运动校正。用于计算灌注,通透性,血液量,间质体积,通过时间和血管大小指数的药代动力学模型包括两个部分,并校正了动脉输入功能的延迟和离散。 双重对比序列提供的信息允许应用更复杂的模型进行评估,并实现所有参数的量化。发现周围前列腺肿瘤与周围健康前列腺组织的灌注不同(1.38 ml /(min> cm3)vs. 0.23 ml /(min> cm3),P = 0.001),血容量大约高出两倍,为1.9%。 0.7%;肿瘤的平均通过时间约为正常前列腺组织的一半,即2.88±2.30 s和4.88±3.21 s。 具有逆转准备的双对比序列,可获取具有足够的时间分辨率和信噪比的T1和T2 *加权图像,已成功应用于前列腺癌患者中,以量化所有流入和流出低分子药物的药代动力学参数重量的惰性示踪剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号